FREE Account Opening + No Clearing Fees
Loading...

Ajanta Pharma Buyback 2024 vs Dwarikesh Sugar Industries Buyback 2024

Comparision between Ajanta Pharma Buyback 2024 and Dwarikesh Sugar Industries Buyback 2024.

Buyback Details

Ajanta Pharma Buyback 2024 is a Tender Offer buyback proposed to list at BSE, NSE while Dwarikesh Sugar Industries Buyback 2024 is a Tender Offer proposed to list at BSE, NSE.

  Ajanta Pharma Limited Dwarikesh Sugar Industries Limited
Logo Ajanta Pharma Buyback 2024 Logo Dwarikesh Sugar Industries Buyback 2024 Logo
Type of Buyback Tender Offer Tender Offer
Listing At BSE, NSE BSE, NSE
Face Value ₹2 per share ₹1 per share
Buyback Price ₹2770 per share ₹105 per share
Issue Size 10,28,881 shares 30,00,000 shares
Issue Size (Amount) ₹285.00 Crores ₹31.50 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders13 Equity Shares out of every 816 Fully paid-up Equity Shares held on the Record Date.710,005.00
General Category for all other Eligible Shareholders13 Equity Shares out of every 816 Fully paid-up Equity Shares held on the Record Date.2,289,995.00
Registrar Link Intime India Private Ltd Link Intime India Private Ltd
Lead Managers Vivro Financial Services Private Limited Centrum Capital Limited
Necessity of the buyback

Buyback is being undertaken, inter-alia, for the following reasons:

  1. The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders;
  2. The Buyback, which is being implemented through the tender offer route as prescribed under the SEBI Buyback Regulations, would involve the allocation of the number of Equity Shares as per their entitlement or 15% of the number of Equity Shares to be bought back whichever is higher, reserved for the small shareholders. The Company believes that this reservation for small shareholders would benefit a large number of public shareholders, who would be classified as "small shareholders" as per Regulation 2(i)(n) of the SEBI Buyback Regulations;
  3. The Buyback may help in improving its earnings per share and return on equity, by reduction in the equity base, thereby leading to a long-term increase in shareholders' value; and
  4. The Buyback gives an option to the shareholders holding Equity Shares of the Company, who can choose to participate and get cash in lieu of Equity Shares to be accepted under the Buyback offer or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer, without additional investment.

The Buyback is being undertaken for the following objectives:

  1. The Buyback will help the Company to distribute surplus funds to its shareholders holding Equity Shares broadly in proportion to their shareholding, thereby, enhancing the overall return to the shareholders and it will also help in improving return on equity, by reducing the equity base, thereby leading to long term increase in shareholders' value;
  2. The Buyback, which is being implemented through the tender offer route as prescribed under the Buyback Regulations, would involve the allocation of a number of equity shares as per the entitlement to the shareholders or 15% of the number of Equity Shares to be bought back whichever is higher, reserved for the small shareholders. The Company believes that this reservation for small shareholders would benefit a large number of public shareholders, who would get classified as "small shareholders" as per Regulation 2(i)(n) of the Buyback Regulations; and
  3. The Buyback gives an option to the Eligible Shareholders to either (a) choose to participate and get cash in lieu of Equity Shares to be accepted under the Buyback or (b) choose to not participate and enjoy a resultant increase in their percentage shareholding, post-Buyback, without additional investment.

Buyback Timetable

Ajanta Pharma Buyback 2024 and Dwarikesh Sugar Industries Buyback 2024 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Ajanta Pharma Buyback 2024 Buyback record date is May 30, 2024. Dwarikesh Sugar Industries Buyback 2024 Buyback record date is Mar 20, 2024.

  Ajanta Pharma Limited Dwarikesh Sugar Industries Limited
Record Date May 30, 2024 Mar 20, 2024
Offer Open Date Mar 27, 2024
Offer Closure Date Apr 03, 2024
Last date for receipt of tender forms Apr 03, 2024
Finalisation of buyback Apr 10, 2024
Last Date for settlment of bids Apr 12, 2024
Last Date for extinguishment of shares Apr 24, 2024

Financial Details and Other Relevent Information

Comparison of Ajanta Pharma Buyback 2024 and Dwarikesh Sugar Industries Buyback 2024 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

  Ajanta Pharma Limited Dwarikesh Sugar Industries Limited
Financial

Ajanta Pharma Limited Financial Information (Restated Consolidated)

Ajanta Pharma Limited's revenue increased by 11.77% and profit after tax (PAT) rose by 38.81% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 2023
Assets4,638.394,679.02
Revenue4,293.313,841.28
Profit After Tax816.17587.98
Amount in ₹ Crore

Dwarikesh Sugar Industries Limited Financial Information (Restated)

Dwarikesh Sugar Industries Limited's revenue increased by 7.07% and profit after tax (PAT) dropped by -32.47% between the financial year ending with March 31, 2023 and March 31, 2022.

Period Ended31 Dec 202331 Mar 202331 Mar 202231 Mar 2021
Assets1,280.011,419.541,445.44
Revenue1,339.182,117.001,977.231,845.94
Profit After Tax60.69104.81155.2291.54
Reserves and Surplus722.59655.44561.42
Total Borrowing371.89523.31608.47
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Feb-2024 86.10 77.89 81.86
Jan-2024 87.72 80.92 85.40
Dec-2023 91.47 83.84 87.67
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Feb-2024 86.10 77.95 81.86
Jan-2024 87.80 80.90 85.36
Dec-2023 91.50 83.80 87.65

Comments

Add a public comment...